Prognostic Panel Helps Identify Lupus Patients at Risk for Kidney, Brain, or Cardiovascular Involvement

Exagen Diagnostics, Inc. (Albuquerque, NM, USA), a leading diagnostics development company focused in rheumatology, has launched the addition of "Avise SLE Prognostic" to its testing services. Designed to supplement the "Avise SLE+ Connective Tissue" diagnostic, the Avise SLE Prognostic panel helps physicians assess potential risk for lupus nephritis, neuropsychiatric SLE (Systemic lupus erythematosus), thrombosis, and cardiovascular events.

The prognostic panel was developed in response to physician requests to help fulfill an unmet need in the rheumatology space. The panel includes the following markers: anti-C1q – prognostic factor for lupus nephritis; anti-Ribosomal P – prognostic factor for neuropsychiatric SLE; and anti-phosphatidylserine/prothrombin (PS/PT) (IgM, IgG) – prognostic factor for thrombosis in SLE. Also, prognostic factors for thrombosis and cardiovascular events – anti-cardiolipin (IgM, IgG, IgA) and anti-β2-Glycoprotein 1 (IgM, IgG, IgA) – are indirectly included in the Avise SLE+ Connective Tissue 2.0 diagnostic or as an add-on to Avise SLE 2.0.

Complimenting Avise SLE 2.0 or Avise SLE+ Connective Tissue 2.0, Avise SLE Prognostic uses the same blood draw specimen as for the diagnostic and offers pre-provided kits, pre-paid Fedex, limited patient out-of-pocket cost, and high quality data based results within 7 days.

"We are pleased to provide an additional tool to help support physicians with their clinical assessment and treatment of patients. This launch furthers our commitment to providing access to quality serologic testing to all patients," said Ron Rocca, Exagen President and CEO.

Related Links:
Exagen Diagnostics
Avise Tests